4
Orphan Designations
0 approved, 4 designated
0
FDA Approvals
0
Active Trials
4
Rare Diseases
across 8 areas
0
News (30d)
Quiet
Calliditas Therapeutics Suisse SA is a company with 4 orphan drug designations across 4 rare diseases.
Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.
Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA
| Disease | Drug(s) | Stage |
|---|---|---|
| Alport syndrome | setanaxib | Des.TrialAppr. |
| idiopathic pulmonary fibrosis | 2-(2-chlorophenyl)-4-[3-(dimethylamino)phenyl]-5-methyl-1H-pyrazolo[4,3-C]pyridine-3,6(2H,5H)-dione | Des.TrialAppr. |
| primary biliary cholangitis | Setanaxib | Des.TrialAppr. |
| systemic sclerosis | (2-(2-chlorophenyl)-4-[3-(dimethylamino)phenyl]-5-methyl-1h-pyrazolo [4,3-c] pyridine-3,6(2h,5h)-dione) | Des.TrialAppr. |
0% of portfolio targets high unmet need diseases
20
overlap in 2+ diseases
0/4
candidate diseases
0
avg importance: 0
0
affecting portfolio
0% of portfolio targets high unmet need diseases
20
overlap in 2+ diseases
0/4
candidate diseases
0
avg importance: 0
0
affecting portfolio